Biomedtech Portfolio

Holistick Medical

Patent Foramen Ovale (PFO) treatment through next generation medical devices

Hollistick's Website

Holistick, founded by Truffle Capital in 2017, is a MedTech focused on revolutionising the treatment of septal heart defects between the left and right heart. Current techniques are cumbersome and are difficult to implant, thus Holistick proposes a minimaly invasive technology that will facilitate implantation.

LATEST NEWS

April 7, 2021

Holistick raises $5M to boost preclinical development of PFO closure device

October 10, 2018

Denis Gestin appointed as Chairman of Holistick Medical – first startup funded by Truffle Capital’s BioMedTech Crossover Fund

March 15, 2018

Truffle Capital’s newly created start-up HoliStick Medical licenses technology from Harvard University and collaborators

OTHER COMPANIES

Seacure

Seacure leverages natural processes to fight against coastal erosion and protect marine structures

Theraclion

Medical devices levaraging Focused Ultrasounds to treat varicose veins, Fibroadenoma and Thyroid...

Theradiag

In-vitro diagnostics for autoimmune diseases

Vexim

Minimally invasive spinal implant

Symetis

Minimaly invasive Aortic Valve

Carmat

First-of its kind implantable artificial heart

Evexta Bio

Developing Next Generation Precision Cancer Therapies

Spikimm

SpikImm develops long-acting mAbs to prevent viral infections in imunocompromized patients, in pa...

PK Med

Locally administered therapeutic products to address inflammatory joint diseases and tissue regen...

Skinosive

Bio-adhesive UV filters for long lasting and broad-spectrum sun protection